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Benzodiazepines (BZDs) are a class of psychotropic drugs that function 
as positive allosteric modulators on the gamma-aminobutyric acid-A 
(GABAA) receptors in the brain.[1] Binding results in the opening of 
chloride ion channels, resulting in the neuron becoming negatively 
charged and resistant to excitation.[1] This process potentiates the 
inhibitory actions of GABA, resulting in a range of clinical effects 
including hypnosis, anxiolysis, and anticonvulsant, myorelaxation 
and amnesic actions.[2] These varying actions have contributed to 
the widespread use of BZDs.[2] BZDs are most commonly used in the 
field of psychiatry, but are also frequently prescribed in epilepsy and 
conditions associated with muscle spasticity.[2] These drugs remain 
popular because they are highly efficacious and fast acting with 
minimal toxicity, and it is not surprising that they are among the most 
frequently prescribed medications globally.[2,3]
Although BZDs have many clinical benefits, there are risks and 
significant disadvantages associated with their use.[2] Adverse effects 
of BZDs include psychomotor retardation, memory impairment, 
paradoxical excitement, emotional blunting and depression.[2,4] The 
main dangers associated with BZD prescription are the risk of 
abuse and physiological and psychological dependence.[2] Tolerance 
may develop with repeated administration and result in dose 
escalation to reach the previous clinical effect.[2] Additionally, abrupt 
discontinuation of BZD use can result in a withdrawal syndrome 
characterised by sleep disturbances, anxiety and irritability.[2] Groups 
at risk include individuals with a history of substance abuse and 
the elderly.[4] Individuals with substance abuse may abuse BZDs 
in combination with other substances that enhance their toxic 
effects and can result in death.[4] Elderly people have decreased 
drug metabolism and increased susceptibility to psychomotor and 
cognitive impairment, which can lead to falls and fractures.[2] The 
above facts raise concern regarding the safe use of BZDs, so clear 
guidelines are recommended for their appropriate prescribing.[5] 
Internationally, many countries have released guidelines on BZD 
prescribing. In South Africa (SA) the standard treatment guidelines 
(STGs) and Western Cape (WC) Provincial Code List recommend 
short-term and limited use.[6,7]
There has been an increase in research on BZD utilisation in most 
countries, with most information coming from developed countries. 
A study in the USA found that BZD prescriptions increased by 67% 
from 1996 to 2013.[8] Another US study found that long-term use of 
BZDs increased with age from 14.7% in patients aged 18 - 35 years 
to 31.4% in those aged 65 - 80 years.[9] There are very limited studies 
on BZD use in developing countries, but the existing research is 
consistent with international data indicating increased use. No 
studies have been conducted in other African countries, and there 
are only a few studies on BZD use in SA. The most noteworthy 
study on the prescribing patterns of BZDs demonstrated an increase 
in prescription claims from 7.3% to 8.0% in two provinces, namely 
the Northern Cape and Gauteng.[10] Two studies in the WC have 
important implications for this study. The first of these found that 
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BZDs were the substances most misused by patients attending 
Cape Town specialist treatment centres from 1998 to 2000, which 
indicates that the WC may be a particularly important setting for 
BZD utilisation research.[3] The second study found that the WC had 
the highest prevalence of mental disorders in SA,[11] highlighting the 
significance of conducting the present study in the WC to determine 
the associated use of BZDs.
Objectives
There is a need for more studies on BZD use in SA. The main 
objectives of the present study were to critically assess prescribing 
patterns of the BZDs most commonly used in the WC and quantify 
the co-prescribing patterns associated with BZD use, and to provide 
insight into prescribing and a platform for remedial action for safer 
and more effective use of medicines.[5] The latter could help control 
drug expenditure and promote more rational prescribing patterns.
Methods
Study sample
This was a descriptive, retrospective quantitative study of prescription 
data from the Western Cape Department of Health (WCDoH). 
The data were obtained from DSV Healthcare, which is a private 
distributor of pharmaceutical and healthcare products. This company 
functions as a dispensary and prepackages patient-ready parcels for 
chronic, stable patients accessing WCDoH facilities. DSV Healthcare 
has been contracted by the WCDoH to supply medicines to public 
health patients.
Only prescriptions received during the month of January 2017 
were included in the study. A total of 331 507 scripts were received by 
DSV Healthcare during this time period. Prescriptions were analysed 
according to BZD use. Four BZDs were reviewed: clonazepam, 
diazepam, lorazepam and oxazepam. These are the only BZDs 
stocked at DSV Healthcare and can be dispensed outside a hospital 
setting.
The inclusion criteria encompassed prescriptions: (i) received by 
the CDU; (ii) that contained at least one BZD item; and (iii) dated 
during January 2017. We excluded prescriptions: (i) that did not 
contain a BZD; (ii) for patients not accessing WCDoH facilities; 
(iii) for patients accessing City of Cape Town Health facilities, which 
are not funded by the National Department of Health; (iv) dated 
outside January 2017; (v) with stat doses, which are not accepted at 
DSV Healthcare; and (vi) for inpatients, as inpatient prescriptions are 
not accepted at DSV Healthcare.
Of the 1 396 prescriptions selected for inclusion, two had missing 
information on patient gender. These were nevertheless included in 
the study, as all the other variables were recorded.
Full ethical approval was obtained from the University of 
KwaZulu-Natal (ref. no. BE246/17) and the WCDoH (ref. no. 
WC_2016RP40_745), and permission to use data was granted by 
DSV Healthcare. 
Sampling, data collection and analysis
The data set was obtained electronically from DSV Healthcare, which 
stores the WCDoH prescriptions. The data set contained prescription 
information in the form of an Excel version 16.19 spreadsheet 
(Microsoft, USA) called a ‘data dump’. The indication for BZDs 
was added manually to the data set according to the International 
Classification of Diseases and Related Health Problems, 10th revision 
(ICD-10).
The completed spreadsheet included BZD type, therapeutic 
indications, patient factors including age and gender, concomitant 
drugs prescribed with BZDs, and demographics including district 
and substructure under each region in the WC. These data were 
coded and analysed using Stata version 14 (StataCorp, USA).
Results were described using frequencies, percentages and 
means (with standard deviations (SDs)). The 25th, 50th and 75th 
percentiles for age were also used. Pearson’s χ2 test was used to assess 
associations between categorical variables, and analysis of variance to 
compare differences in age between BZD users. A p-value <0.05 was 
considered to be statistically significant. Data were analysed using 
Stata version 14.
In addition, concomitant medication use associated with BZD 
prescribing was identified by grouping medications into drug 
classes and identifying the most frequent concomitant drug classes 
prescribed.
Results
Prescribing patterns per district
A total of nine substructures were analysed, each belonging to either 
the metropolitan district or the rural district. The metropolitan 
district constituted four substructures: Eastern Khayelitsha, Northern 
Tygerberg, South Western and Klipfontein/Mitchell’s Plain. The rural 
district constituted five substructures: Cape Winelands, Central 
Karoo, Eden, Overberg and West Coast.
Of the 1 396 prescriptions analysed, the majority were from the 
metropolitan district (n= 969, 69.4%) as opposed to the rural district 
(n=427, 30.6%). The prescribing frequency for BZDs per district is 
presented in Table 1.
Overall, clonazepam was the most frequently prescribed BZD 
(n=691, 49.5%), accounting for approximately half of the total 
number of BZD prescriptions. Diazepam was the second most 
frequently prescribed (n=298, 21.4%) followed by lorazepam (n=222, 
15.9%) and oxazepam (n=185, 13.3%). Clonazepam was the most 
frequently prescribed BZD in both the metropolitan and rural 
districts (metropolitan 45.0% and rural 59.7%).
Oxazepam was the BZD with the lowest prescribing frequency in 
the metropolitan district (11.0%), while lorazepam was the BZD with 
the lowest prescribing frequency in the rural district (8.2%).
Prescribing patterns per substructure
Benzodiazepine prescribing frequency in the different substructures 
is presented in Table 2. Northern Tygerberg had the highest number 
of BZD prescriptions (n=400, 28.7%) while Central Karoo had the 
lowest (n=19, 1.4%).
Overall, clonazepam was the most frequently prescribed BZD 
among the substructures, with the exception of Klipfontein/Mitchell’s 
Plain, where diazepam was prescribed more frequently (n=54, 38.0%) 
than clonazepam (n=51, 35.9%). The least prescribed BZD differed 
for each substructure, with oxazepam having the lowest prescribing 
frequency in five out of the nine substructures.
Table 1. Benzodiazepine prescribing in metropolitan and rural districts, n (%)
District Clonazepam Diazepam Lorazepam Oxazepam Total
Metropolitan 436 (45.0) 239 (24.7) 187 (19.3) 107 (11.0) 969 (100)
Rural 255 (59.7) 59 (13.8) 35 (8.2) 78 (18.3) 427 (100)
Total 691 (49.5) 298 (21.4) 222 (15.9) 185 (13.3) 1 396 (100)
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Analysis of benzodiazepine prescribing related to 
patient demographics
Prescribing patterns associated with gender (Table 3)
There were statistically more females (n=793 prescriptions, 56.9%) 
receiving BZDs than males (n=601, 43.1%) (p<0.001). Clonazepam 
was the most frequently prescribed BZD for both females (n=412, 
52.0%) and males (n=278, 46.3%).
The least prescribed BZD differed according to gender. Diazepam 
was the least prescribed BZD in females (n=118, 14.9%), while 
oxazepam was the least prescribed in males (n=51, 8.4%).
Prescribing patterns associated with age (Table 4)
The ages of patients receiving prescriptions for BZDs ranged from 1 
to 98 years, with a mean (SD) of 51.3 (19.6). The mean (SD) ages of 
patients receiving clonazepam and lorazepam were 51.7 (16.7) years 
and 52.4 (20.1) years, respectively.
Diazepam tended to be prescribed to younger patients (mean 
(SD) 40.57 (21.7) years) and oxazepam to older patients (65.3 (15.1) 
years). Age differed significantly between users of the different BZDs 
(p<0.0001), with the exception of clonazepam and lorazepam. The 
25th, 50th and 75th percentiles were 39, 53 and 65 years, indicating 
that in the main the ages of the population of BZD users ranged from 
middle adulthood to elderly (34 - 60 years).
Prescribing patterns associated with benzodiazepine indication
The indications most frequently listed for BZD use in the WC are 
reported in Table 5. The most common therapeutic indication was 
epilepsy (n=294 prescriptions, 21.1%) followed by depression (n=166, 
11.9%) and depression with concomitant anxiety (n=79, 5.7%).
Concomitant medication prescribing
The data were analysed to identify concomitant medications 
associated with BZD use (Table 6). This analysis was done by 
grouping drug classes together.
A total of 9 026 concomitant drugs were found in the 1 396 
prescriptions included in this study. The most common concomitant 
drug class prescribed was antiepileptics (n=1 581 prescriptions), 
followed by other BZDs (n=706) and analgesics and antipyretics 
(n=665). Other significant co-prescribed drug classes included 
selective serotonin reuptake inhibitors (n=379) and tricyclic anti-
depressants (n=220).
Discussion
Multiple studies on BZD use have been done in developed countries, 
but there has been little similar research in SA. This is the first study 
to report BZD prescribing patterns in the WC public healthcare 
setting.
The study reviewed 1 396 BZD prescriptions for the month of 
January 2017 in the WC. The majority were from the metropolitan 
district, which has a larger populations than the rural district, 
resulting in more people accessing public healthcare facilities and an 
increased likelihood of being prescribed a BZD.[12]
We found that of the four BZDs reviewed, clonazepam was the most 
frequently prescribed in both the metropolitan and rural districts, 
followed by diazepam, lorazepam and oxazepam. Prescription of 
BZDs is heavily regulated in the WC.[7] According to the Provincial 
Code List, prescription of a BZD should not exceed 14 days except 
in the case of specialist referral under certain conditions including 
epilepsy and cerebral palsy and severe muscle spasms in children. [7] 
Table 2. Benzodiazepine prescribing in Western Cape substructures, n (%)
Substructure Clonazepam Diazepam Lorazepam Oxazepam Total
Eastern Khayelitsha 76 (43.2) 49 (27.8) 33 (18.8) 18 (10.2) 176 (100)
Northern Tygerberg 206 (51.5) 73 (18.3) 72 (18.0) 49 (12.3) 400 (100)
South Western 103 (41.0) 63 (25.1) 54 (21.5) 31 (12.4) 251 (100)
Klipfontein/Mitchell’s Plain 51 (35.9) 54 (38.0) 28 (19.7) 9 (6.3) 142 (100)
Cape Winelands 38 (52.0) 10 (13.7) 3 (4.1) 22 (30.1) 73 (100)
Central Karoo 8 (42.1) 2 (10.5) 4 (21.1) 5 (26.3) 19 (100)
Eden 171 (71.9) 16 (6.7) 16 (6.7) 35 (14.7) 238 (100)
Overberg 19 (32.8) 16 (27.6) 9 (15.5) 14 (24.1) 58 (100)
West Coast 19 (48.7) 15 (38.5) 3 (7.7) 2 (5.1) 39 (100)
Total 691 (49.5) 298 (21.4) 222 (15.9) 185 (13.2) 1 396 (100)
Table 3. Benzodiazepine prescription according to gender, n (%)
Gender Clonazepam Diazepam Lorazepam Oxazepam Total*
Male 278 (46.3) 180 (30.0) 92 (15.3) 51 (8.5) 601 (100)
Female 412 (52.0) 118 (14.9) 129 (16.3) 134 (16.9) 793 (100)
Total 690 (49.5) 298 (21.4) 221 (15.9) 185 (13.3) 1 394 (100)
*There were two missing values for gender, giving a total of 1 394 prescriptions instead of 1 396.
Table 4. Benzodiazepine prescription related to age (years)
Benzodiazepine n Mean SD Min. p25 p50 p75 Max.
Clonazepam 691 51.7 16.7 1 42 52 63 91
Diazepam 298 40.6 21.7 1 22 42 58 94
Lorazepam 222 52.4 20.1 4 41 54 67 94
Oxazepam 185 65.3 15.1 21 55 67 76 98
Total 1 396 51.3 19.6 1 39 53 65 98
SD = standard deviation; Min. = minimum; p = percentile; Max. = maximum.
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The high prescription rate for clonazepam is probably due to less 
strict restrictions for clonazepam that permit its longer-term use in 
epilepsy[7] and may result in repeat prescriptions and chronic use of 
this agent.
Additionally, clonazepam is classified as a long-acting BZD. Some 
prescribers prefer long-acting BZDs due to an increase in dosing 
intervals, which contribute to its popularity among prescribers and 
patients.[2] A study from a mental healthcare facility in the USA in 
patients with depression found long-acting (half-life >24 hours) 
clonazepam to be the most frequently prescribed BZD.[13] Similarly, 
a study in Brazil’s public healthcare sector assessing dependence and 
anxiety in BZD users also found clonazepam to be the most widely 
used BZD.[13,14] There are no studies on BZD utilisation from African 
countries other than SA. Notably, two of the four studies from SA also 
demonstrated that long-acting BZDs are most commonly used. [15,16] 
A 2007 study by Kairuz and Truter[15] in the private sector in SA 
found that diazepam, a BZD with a half-life similar to clonazepam, 
was the most frequently prescribed BZD. Earlier, in 1990, Summers 
et  al. [16] demonstrated that the majority of BZDs prescribed in a 
public hospital in SA fell into the long-acting and intermediate-acting 
categories, showing that this bias exists across the healthcare sector. 
The frequent prescribing of clonazepam in our study can therefore 
probably be ascribed to both a convenient dosing interval and high 
rates of the chronic conditions that this drug is used for.
In the present study, diazepam was the second most commonly 
prescribed BZD overall. Like the more often prescribed clonazepam, 
diazepam also has less strict restrictions in the WC that allow its 
use in children with cerebral palsy and severe muscle spasms[7] 
and may be a contributory factor in its high rate of use. In the 
available literature, short-acting BZDs are prescribed more frequently 
than their longer-acting counterparts.[9,17] A meta-analysis from a 
longitudinal prescription database that included ~60% of all retail 
pharmacies in the USA demonstrated that only one-quarter of 
individuals receiving BZDs used long-acting agents.[9]
Lorazepam and oxazepam had lower prescription rates overall 
than the other BZDs, probably because they are recommended 
for restricted and short-term use in clinical indications that are 
less prevalent than conditions other BZDs are used for. A study 
in Pakistan investigating BZD use in outpatient clinics found that 
alprazolam, a short-acting BZD, was most commonly used in patients 
with cardiovascular problems.[18] A cross-sectional Lebanese study 
assessing BZD prescription patterns also found that short-acting 
Table 5. Most common therapeutic indications associated with benzodiazepine prescription in the Western Cape in January 2017
Diagnosis ICD-10 Frequency, n
1.   Epilepsy G40.90 294
2.    Depression F32 166
3.    Depression + anxiety F32. + F41.9 79
4.    Bipolar mood disorder F31 62
5.    Anxiety F41.9 60
6.    Epilepsy + cerebral palsy G40.90 + G80 60
7.    Schizophrenia F20 50
8.    Paraplegia G82.2 42
9.    Parkinson’s disease G20 42
10. Cerebral palsy G80 41
11. Quadriplegia G82.50 41
12. Insomnia G47 39
13. Hypertension I10 38
14. Dementia F03 30
15. Epilepsy + depression G40.90 + F32 29
16. Spinal cord injury T09.3 13
17. Depression + insomnia F32. + G47 12
18. Depression + psychosis F32. + F29 11
19. Epilepsy + psychosis G40.90 + F29 10
20. Schizoaffective disorder F25 10
ICD-10 = International Classification of Diseases and Related Health Problems, 10th revision.
Table 6. Most common concomitant drug classes associated 
with benzodiazepine prescription in the Western Cape in 
January 2017
Drug classes Frequency
1.    Antiepileptic 1 581
2.    Benzodiazepines 706
3.    Analgesics and antipyretics 665
4.    Diuretics 497
5.    Statins 383
6.    Selective serotonin reuptake inhibitors 379
7.    Angiotensin-converting enzyme inhibitors 328
8.    Others (ointments, risperidone, leflunomide) 276
9.    Calcium channel blockers 264
10. Proton pump inhibitors 252
11. Tricyclic antidepressants 220
12. Oral agents (metformin, glimepiride) 209
13. Other (tramadol) 202
14. Laxatives 194
15. Haematinics 180
16. Antivertigo and antiemetic agents 167
17. Centrally acting muscle relaxants (baclofen) 157
18. Antianginal agents 150
19. Single vitamins 135
20. Antihistamines 97
Total 7 042
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BZDs were frequently prescribed.[19] These results highlight the fact 
that while long-acting BZDs are most commonly prescribed in many 
countries, short-acting ones are still preferred in others. Short-acting 
BZDs may be prescribed more frequently because of their usefulness 
in certain populations. The Beers Criteria, for example, recommend 
the use of short-acting BZDs rather than longer-acting agents in 
geriatric patients.[20] The Beers Criteria suggest that short-acting 
BZDs are safer than long-acting ones in patients aged >65 years 
because the latter can cause prolonged sedation, increasing the risk 
of falls and fractures in the elderly.[20]
A study in the USA on BZD use from January 2008 to December 
2008 found a general increase in the use of these agents with age, 
with the highest increase of 8.7% in individuals aged 65 - 80 years. [9] 
A study in Norway evaluating a prescription database from 2004 to 
2009 found that the mean age of BZD users was 62 years, almost 
10 years older than the mean age in our study.[21] Patients in older 
age groups tend to have an increased disease burden, especially 
with regard to neurocognitive and neuropsychiatric conditions and 
chronic pain syndrome, which may explain the increased use of BZDs 
in the elderly.[9] A study in Brazil assessing dependence and anxiety in 
BZD users found that those with the highest rate of use were between 
61 and 70 years of age, again indicating an older age group compared 
with our study. In the current study, the majority of the patients 
prescribed BZDs were adults aged 34 - 60 years.[14]
Interestingly, a study in Pakistan reviewing BZD use in outpatient 
clinics found the average age of BZD users to be 45 years, which is 
much younger than in our study.[18] Similarly, an SA study in 2004 
reviewing BZD prescriptions from private healthcare patients found 
the mean age to be 43.17 years.[15] Another study conducted in the 
private healthcare sector of SA in Gauteng and Northern Cape 
provinces found that patients aged 40 - 65 years had the highest rate 
of BZD prescriptions.[10] It is important to note that use of BZDs 
is not recommended in elderly patients, as the half-lives of BZDs 
are increased in the elderly, leading to toxicity and an increase in 
the likelihood of falls and fractures.[4] Guidelines such as the Beers 
Criteria therefore suggest that the elderly should use short-acting 
agents in the short term only.[20]
The present study found that significantly more females than males 
were prescribed BZDs. This is consistent with other reports high-
lighting a higher prevalence of BZD prescriptions in females. [9,13,14] 
Three of the four studies that reviewed BZD use in SA found it 
to be higher in females (the fourth study did not analyse gender 
differences).[10,15-17] Epidemiological data suggest that females tend to 
have a higher prevalence of depression and anxiety than males, which 
are common therapeutic indications for BZDs.[2,22] This correlates 
with our finding that depression and depression and anxiety were 
the therapeutic conditions most often treated with a regimen that 
included a BZD. Additionally, studies suggest that females are more 
inclined to use medication and access health services than males, 
resulting in a greater likelihood of BZD use.[14]
The most common therapeutic indication for prescription of a 
BZD in our study was epilepsy (n=294 prescriptions, 21.1%). This 
finding is not surprising, as the WC approves the use of clonazepam 
in epilepsy.[7] The STGs indicate that epileptic conditions such as 
generalised tonic-clonic seizures and partial seizures should be treated 
with anticonvulsant medications such as carbamazepine, lamotrigine, 
phenytoin or valproate.[6] However, the STGs recommend that 
absence seizures and myoclonic seizures should be referred for 
specialist consultation.[6] A specialist can approve the prescription of 
clonazepam as adjuvant therapy in absence seizures and myoclonic 
seizures in this setting. Guidelines from the National Institute for 
Health and Care Excellence (NICE) indicate that BZDs can be used 
as alternative agents in the treatment of atypical absence seizures, 
myoclonic seizures and idiopathic generalised epilepsy, which is in 
line with the STGs.[23]
The most frequent concomitant drug class prescribed with 
BZDs was antiepileptic drugs. Benzodiazepines can be used in 
the management of epileptic conditions, as they act by decreasing 
the duration and spread of seizures.[24] They are still frequently 
prescribed as an adjunct to other antiepileptics in the management 
of epilepsy when monotherapy is ineffective, as they produce 
pharmacological synergism.[25] Additionally, BZDs have been 
proven to be valuable in the emergency management of status 
epilepticus, where they are first-line agents in most management 
protocols.[2]
The second most common therapeutic indication for BZD 
prescribing was depression. Studies in the USA have found 
depression to be the most common therapeutic indication for BZD 
prescription upon discharge,[13,22] while in developing countries 
such as Thailand and Lebanon depression has been identified as 
the third most common therapeutic indication.[19,26] These findings 
demonstrate the worldwide prevalence of BZD use in depression.
The third most common therapeutic indication for BZD 
prescribing was depression with concomitant anxiety. Anxiety and 
depression are very common comorbid disease states that present 
with similar symptoms[27] and are therefore grouped together. 
A study in the USA on BZD use in older patients in a primary 
care setting found that anxiety was a common indication for 
BZD use.[28] Additionally, studies in Thailand and Lebanon have 
identified anxiety as the main indication for BZD prescription, 
which indicates that these comorbid states are commonly treated 
with BZDs.[19,26] The high prevalence of anxiety as a therapeutic 
indication combined with a high prevalence of depression means 
that BZDs are commonly used in these comorbid states.
The second most frequent concomitant drug class prescribed 
with a BZD was a second BZD. There is no therapeutic basis for the 
use of more than one BZD in the same patient, because BZDs all 
have the same mechanism of therapeutic action, differing only with 
regard to pharmacokinetic properties.[29] A study on co-prescription 
of BZDs in Norway found the practice of using more than one BZD 
concomitantly to be widespread, and often initiated by the same 
prescriber.[29]
Study limitations
This study was restricted to prescriptions sent to a WCDoH CDU, so 
there is no way of knowing the true number of patients prescribed 
BZDs in the WC, as some pharmacies may choose to manage patients 
at facility level. Prescriptions from City of Cape Town facilities were 
excluded, and this study on BZD prescription in the WC therefore 
has incomplete data.
This study only reviewed prescriptions in the public healthcare 
sector, which is highly regulated in terms of the Essential Drugs List 
(EDL). The EDL provides a subset of drugs available for prescription 
that is limited to specialist doctors. This provides a unique platform 
for drug use patterns that cannot be transposed onto the private 
healthcare sector, which has a wider variety of drugs and spectrum 
of use. Additionally, any clinician can prescribe BZDs, which creates 
further disparity between research conducted in the private and 
public healthcare sectors.
The fact that only prescriptions dispensed in the month of 
January 2017 were reviewed also means that information on BZD 
prescription patterns is limited.
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Conclusions
The present study confirmed the findings of other researchers that 
female patients and patients in older age groups are most likely to be 
prescribed BZDs. We found clonazepam to be the most frequently 
prescribed BZD, which is in keeping with other studies showing a 
preference for long-acting BZDs.
The study found the use of BZDs to be rational, taking into account 
the therapeutic indications and types of BZDs prescribed, as well as 
the use of concomitant drug therapy.
Future research reviewing BZD use should include the private 
healthcare sector, to provide greater insight and create greater 
generalisability on BZD prescribing patterns. Additionally, using a 
longer time frame and including City of Cape Town prescriptions would 
give a fuller understanding of BZD prescription patterns in the WC.
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